Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06946784

LIFE-TB ; Long-Term Impacts on Lung Health and Life After Tuberculosis in Korea

This is a prospective, multicenter observational cohort study aimed at establishing a nationwide post-TB lung disease registry in Korea. The study will enroll adult participants either undergoing treatment for pulmonary tuberculosis or with a history of treated TB. Over a five-year follow-up period, the study will assess the long-term health consequences of TB, focusing on respiratory symptoms, radiological changes, pulmonary function, and quality of life.

Recruiting

Interested in participating?

Request Info

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Internal Medicine, Yonsei University College of Medicine Division of Pulmonology, Severance Hospital, Yonsei University Health System

Seoul, South Korea

Location status: Recruiting

Location contact

Young Ae Kang

CONTACT

[email protected]

+82-2-2228-1986

About this study

"The LIFE-TB (Long-Term Impacts on Lung Health and Life After Tuberculosis in Korea) study is a nationwide, prospective, multicenter observational cohort designed to systematically investigate the long-term impacts of tuberculosis (TB) on lung health and quality of life. This registry aims to fill the critical evidence gap in understanding post-TB lung disease (PTLD) by enrolling adults with a current diagnosis of pulmonary TB or a history of TB treatment.

Participants will be recruited from six tertiary care centers across Korea. Eligible individuals include those aged 19 or older who are either undergoing anti-TB treatment or have completed it. Exclusion criteria include extrapulmonary TB without lung involvement, age under 19, or refusal to consent.

Data will be collected at baseline and regularly over a five-year follow-up period. Clinical variables include demographic information (age, sex, BMI, smoking status), TB-related history (sputum smear/culture, drug resistance, treatment outcomes), comorbidities, and current medications. Clinical assessments involve standardized symptom scores (mMRC), chest imaging (X-ray and CT), spirometry, and validated instruments to assess quality of life (EQ-5D-5L, PROMIS, SGRQ). Laboratory data include blood tests (HbA1c, lipids), HIV/HBV/HCV status, and urine and ECG assessments at baseline.

Participants will be followed annually, with interim assessments including imaging, spirometry, and symptom scoring at specified intervals. No study-specific interventions or additional imaging are required beyond routine care. Chest CTs will only be collected if obtained for clinical purposes.

The study's primary objectives are to describe the prevalence and trajectory of PTLD-related abnormalities and identify factors associated with poor outcomes. Secondary analyses include trends in pulmonary function and quality of life over time, as well as health utilization patterns. Statistical analyses include descriptive statistics and multivariable logistic regression to identify risk factors.

All data will be anonymized and securely stored, following institutional and ethical guidelines. The study will contribute essential real-world data to inform national and international post-TB management strategies."

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥19 years
  • Diagnosed with pulmonary TB and either initiating or undergoing treatment or history of treated pulmonary TB

Exclusion criteria

  • Age <19 years
  • Extrapulmonary TB without lung involvement
  • Refusal to provide informed consent

Treatment and study plan

Primary outcomes

  1. respiratory symptoms

    Time frame: 6month , 1year, 2year, 3year, 4year, 5year, 6year

    Prevalence and progression of respiratory symptoms (mMRC score, cough, sputum, hemoptysis)

  2. abnormal radiographic findings

    Time frame: 6month , 1year, 2year, 3year, 4year, 5year, 6year

    abnormal findings of chest X-ray or chest CT

  3. pulmonary function

    Time frame: 6month , 1year, 2year, 3year, 4year, 5year, 6year

    Pulmonary function measured by spirometry: FEV1, FVC, FEV1/FVC

  4. Quality of life

    Time frame: 6month , 1year, 2year, 3year, 4year, 5year, 6year

    Quality of life measured by EQ-5D-5L, PROMIS, SGRQ

Secondary outcomes

  1. poor long-term outcome

    Time frame: 6month , 1year, 2year, 3year, 4year, 5year, 6year

    Association of poor long-term outcomes with demographic and clinical variables (age, sex, BMI, comorbidities)

Sponsors and collaborators

Lead sponsor

Yonsei University

Other

Registry information

Important dates

Study start
2025
Primary completion
2031
Study completion
2031
First posted
Apr 27, 2025
Registry last updated
Apr 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.